Kamada

KMDA

Market cap $405M

Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.

Kamada Ltd. ( KMDA ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division James Sidoti - Sidoti & Company, LLC Presentation Operator Good morning.

While the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Kamada (KMDA) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.

REHOVOT, Israel, and HOBOKEN, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months and nine months ended September 30, 2025.

Beyond analysts' top-and-bottom-line estimates for Kamada (KMDA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Kamada (KMDA) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?

The mean of analysts' price targets for Kamada (KMDA) points to an 113.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.